

AUG. 21. 2007 12:49PM

NOVARTIS C. I. P. (973) 781-8064

NO. 8148 P. 1

Gregory D. Ferraro  
Senior Patent Attorney  
Metabolic & Cardiovascular  
Disease (MCD)

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover NJ 07936-1080



Tel (862) 778-7831  
Fax (973) 781-8064  
Internet: gregory.ferraro  
@novartis.com

RECEIVED  
CENTRAL FAX CENTER  
AUG 21 2007

Fax

Attention Office of Patent & Legal Administration  
Patent & Trademark Office  
Alexandria, VA

Fax no. (571)273-8300  
Number of pages 3 including cover page

Date August 21, 2007

Concerning Case 33529-US-PCT - Application No. 10/580,295

Enclosed is a "Letter to Correct a Publication Application" for the above-mentioned application.  
Thank you for your help in this matter.

Very truly yours,

A handwritten signature in cursive script, appearing to read 'Greg Ferraro', written over a horizontal line.

Gregory D. Ferraro

GDF:

CONFIDENTIALITY NOTICE

THIS FAX CONTAINS CONFIDENTIAL INFORMATION WHICH MAY BE PRIVILEGED AND IS INTENDED SOLELY FOR THE USE OF THE ABOVE-NAMED RECIPIENT(S). IT MAY BE EXEMPT FROM DISCLOSURE UNDER APPLICABLE LAW. IF YOU ARE NOT AN INTENDED RECIPIENT OR PERSON RESPONSIBLE FOR DELIVERY OF THIS FAX TO AN INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT YOU HAVE RECEIVED THIS FAX IN ERROR AND THAT ANY REVIEW, DISSEMINATION, DISCLOSURE, COPYING OR OTHER USE OF THIS FAX OR ITS CONTENTS IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS FAX IN ERROR, PLEASE NOTIFY THE SENDER IMMEDIATELY BY TELEPHONE AT ONE OF THE PHONE NUMBERS SET FORTH ABOVE AND DESTROY THIS FAX IMMEDIATELY.

CASE 33529-US-PCT

**CERTIFICATE OF FACSIMILE TRANSMISSION**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Dolores DeCarminis  
Type or print name

Dolores DeCarminis  
Signature

8/21/2007  
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED  
CENTRAL FAX CENTER  
AUG 21 2007

IN RE APPLICATION OF

Art Unit: 1614

SELLNER ET AL.

APPLICATION NO: 10/580,295

FILED: MAY 23, 2006

FOR: DELTA-AMINO-GAMMA-HYDROXY-OMEGA-ARYL-ALKANOIC  
ACID AMIDES AND USE AS RENIN INHIBITORS

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

LETTER TO CORRECT A PUBLICATION APPLICATION

Sir:

Upon review of the instant Publication No. US-2007-0142475-A1, Applicants noted that a Patent Office error appears on page 17 of the publication. The error in claim 6, line 11 should read: "butyric acid (1S, 2S, 4S)-2-amino-1-[(S)-2-(2-carbamoyl-2-" **not** "butyric acid (1S,2S,4S,4S)-2-amino-1-[(S)-2-(2-carbamoyl-2-" and the location of the support is on page 35, line 7, of claim 6 of the specification (a copy is attached herewith).

Please correct this error.

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7831  
GDF:dd

Date: August 21, 2007


Gregory D. Ferraro  
Gregory D. Ferraro  
Attorney for Applicants  
Reg. No. 36,134

Case 33529-US-PCT  
Application No. 10/580,295

WO 2005/054177

PCT/EP2004/013589

- 35 -



(1B),

or a pharmaceutically acceptable salt thereof, wherein  $R^9$  is  $C_1$ - $C_4$ -alkanoyl or a group of the formula  $-COCHR^{14}NH_2$  wherein  $R^{14}$  is  $C_1$ - $C_4$ -alkyl, such as isopropyl or isobutyl, or phenyl- $C_1$ - $C_2$ -alkyl, such as benzyl.

6. A compound according to any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof selected from the group consisting of  
acetic acid (1S,2S,4S)-2-amino-1-[(S)-2-(2-carbamoyl-2-methyl-propylcarbamoyl)-3-methyl-butyl]-4-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-5-methyl-hexyl ester;  
propionic acid (1S,2S,4S)-2-amino-1-[(S)-2-(2-carbamoyl-2-methyl-propylcarbamoyl)-3-methyl-butyl]-4-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-5-methyl-hexyl ester;  
butyric acid (1S,2S,4S)-2-amino-1-[(S)-2-(2-carbamoyl-2-methyl-propylcarbamoyl)-3-methyl-butyl]-4-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-5-methyl-hexyl ester;  
isobutyric acid (1S,2S,4S)-2-amino-1-[(S)-2-(2-carbamoyl-2-methyl-propylcarbamoyl)-3-methyl-butyl]-4-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-5-methyl-hexyl ester;M  
2,2-dimethyl-propionic acid (1S,2S,4S)-2-amino-1-[(S)-2-(2-carbamoyl-2-methyl-propylcarbamoyl)-3-methyl-butyl]-4-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-5-methyl-hexyl ester;  
(S)-2-amino-3-methyl-butyl acid (1S,2S,4S)-2-amino-1-[(S)-2-(2-carbamoyl-2-methyl-propylcarbamoyl)-3-methyl-butyl]-4-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-5-methyl-hexyl Ester;  
(S)-2-amino-4-methyl-pentanoic acid (1S,2S,4S)-2-amino-1-[(S)-2-(2-carbamoyl-2-methyl-propylcarbamoyl)-3-methyl-butyl]-4-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-5-methyl-hexyl ester; and  
(S)-2-amino-3-phenyl-propionic acid (1S,2S,4S)-2-amino-1-[(S)-2-(2-carbamoyl-2-methyl-propylcarbamoyl)-3-methyl-butyl]-4-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-5-methyl-hexyl ester.